Is Kyverna Therapeutics, Inc. profitable?

Kyverna Therapeutics, Inc. is not currently profitable: it reported a net loss of $156.4M over the trailing twelve months.

What is Kyverna Therapeutics, Inc.'s earnings per share?

Kyverna Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-3.27.

Where does Kyverna Therapeutics, Inc.'s income statement data come from?

Every line is extracted from Kyverna Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Kyverna Therapeutics, Inc. KYTX Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Research and development	$126.36M-5.5%	$133.72M-2.5%	$137.19M+0.9%	$135.93M+6.7%	$127.43M+13.3%
General and administrative	$37.43M+3.7%	$36.11M+5.0%	$34.4M-3.7%	$35.7M+7.5%	$33.22M+10.3%
Other operating expenses	$163.79M-3.6%	$169.83M-1.0%	$171.59M0.0%	$171.63M+6.8%	$160.65M+12.7%
Total operating expenses	$163.79M-3.6%	$169.83M-1.0%	$171.59M0.0%	$171.63M+6.8%	$160.65M+12.7%
Operating income	-$163.79M+3.6%	-$169.83M+1.0%	-$171.59M0.0%	-$171.63M-6.8%	-$160.65M-12.7%
Interest expense	$1.13M+131%	$490K+571%	$73K-25.5%	$98K-20.3%	$123K-13.4%
Interest income	$8.6M-5.5%	$9.09M-15.5%	$10.76M-18.0%	$13.12M-15.1%	$15.45M+0.6%
Other income (expense), net	$7.39M-13.3%	$8.52M-19.6%	$10.59M-18.1%	$12.93M-15.1%	$15.24M+0.7%
Net income	-$156.4M+3.0%	-$161.31M-0.2%	-$160.99M-1.4%	-$158.7M-9.1%	-$145.42M-14.1%
Diluted earnings per share	-$3.27+10.2%	-$3.64+2.4%	-$3.73-1.4%	-$3.68-8.9%	-$3.38+2.6%
Basic earnings per share	-$3.27+10.2%	-$3.64+2.4%	-$3.73-1.4%	-$3.68-8.9%	-$3.38+2.6%
Weighted-average shares, diluted	191.3M+9.9%	174.1M+3.5%	168.2M+0.2%	167.9M+0.1%	167.8M+13.1%
Weighted-average shares, basic	191.3M+9.9%	174.1M+3.5%	168.2M+0.2%	167.9M+0.1%	167.8M+13.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$156.5M+3.0%	-$161.32M-0.1%	-$161.12M-1.5%	-$158.68M-9.1%	-$145.42M-14.2%
Unrealized gains (losses) on available-for-sale securities	——	——	——	——	——
Other income, net (Note 6)	——	——	-$101K-8.6%	-$93K+2.1%	-$95K-1.1%
EBIT	-$163.79M+3.6%	-$169.83M+1.0%	-$171.59M0.0%	-$171.63M-6.8%	-$160.65M-12.7%
EBITDA	-$162.14M+3.5%	-$168.03M+0.9%	-$169.59M-0.1%	-$169.49M-6.9%	-$158.5M-12.8%
EBITDA	-$162.14M+3.5%	-$168.03M+0.9%	-$169.59M-0.1%	-$169.49M-6.9%	-$158.5M-12.8%
EBIT	-$163.79M+3.6%	-$169.83M+1.0%	-$171.59M0.0%	-$171.63M-6.8%	-$160.65M-12.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Kyverna Therapeutics, Inc. profitable?: Kyverna Therapeutics, Inc. is not currently profitable: it reported a net loss of $156.4M over the trailing twelve months.
What is Kyverna Therapeutics, Inc.'s earnings per share?: Kyverna Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-3.27.
Where does Kyverna Therapeutics, Inc.'s income statement data come from?: Every line is extracted from Kyverna Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.